Pioneer of iPS cells touts technology's benefit to drug development

05/3/2010 | Times (London) (subscription required), The

The use of induced pluripotent stem cells in in vitro trials would reduce the need for animal testing of experimental drugs, said Jamie Thomson, a professor at the University of Wisconsin and one of the pioneers of iPS technology. Thomson said iPS cells would be more cost-effective as laboratory models for disease and drug research rather than being used to create tissue, allowing scientists to "learn a tremendous amount about the human body" and "profoundly change human medicine."

View Full Article in:

Times (London) (subscription required), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ